Germline Signature Predicts Adverse Effects With Anti-PD1/PDL1 Checkpoint Therapy
February 9th 2022Applying these findings in practice could improve clinicians’ ability to offer truly personalized cancer therapy by enabling consideration of toxicity along with other data predicting patients’ responses.
Read More